2018 / 06

Next Paper
DOI: 10.24075/brsmu.2018.089

ORIGINAL RESEARCH

Experimental study of dendrimer-based nanoparticles with RGD-peptide for anticancer radionuclide therapy

Stukalov YuV1, Grigorieva EYu1, Smirnova AV1,3, Lipengolts AA1,2, Kubasova IYu1, Pozdniakova NV1, Lukashina MI4
About authors

1 Blokhin National Medical Research Center of Oncology, Moscow

2 Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russia

3 The Loginov Moscow Clinical Scientific Center, Moscow, Russia

4 Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow

Correspondеnce should be adressed: Elena Yu. Grigorieva
Kashirskoe shosse, 24, Moscow, 115478; ur.liam@11nele-girg

Received: 2018-09-12 Accepted: 2018-10-11 Published online: 2018-12-31
|
Fig. 1. The nanoplatform based on the dendrimer conjugated to the RGD peptide
Fig. 2. Dynamics of 188Re-NP and 188Re accumulation (% of the injected amount per 1 g of tissue) in the subcutaneously transplanted LLC1male in male С57Bl/6 mice
Fig. 3. The growth dynamics of the subcutaneously transplanted LLC1 tumor in С57Bl/6 mice following a single injection of 188Re-NP taken at different 188Re doses (А) and a single injection of 188Re sodium perrhenate and 188Re -NP (188Re dose = 185 MBq/kg) (B)
Table 1. Dynamics of 188Re-NP and 188Re accumulation in the organs and tissues of mice with subcutaneously transplanted LLC1 cells (expressed as % from the injected amount per 1 g of the organ/tissue)
Table 2. Comparison of tumor-to-normal uptake ratio of 188Re-NP and 188Re by the organs and tissues of experimental mice
Table 3. The therapeutic effect of the 188Re-NP against the LLC1 carcinoma
Note: The table shows the results of therapeutic efficacy assessment on days 7, 14 and 18 after drug administration.